An Open-Label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy who Previously Completed Phase 3 Study ISEE2008 (GATHER2)

1. Astellas Pharma Global Development $1,525,757 200 payments

1. Sierra Eye Associates Organisation paid for research $178,833 27 payments
2. Cumberland Valley Retina Consultants Organisation paid for research $92,846 2 payments
3. Southwest Retina Specialists Organisation paid for research $87,332 2 payments
4. Retina Foundation Of The Southwest Organisation paid for research $79,881 6 payments
5. Retina Consultants Of Orange County Organisation paid for research $70,686 2 payments
6. Retina Research Institute Of Texas Organisation paid for research $67,240 3 payments
7. Retina Vitreous Surgeons Of Central New York Organisation paid for research $61,769 2 payments
8. The Retina Group of Washington Organisation paid for research $49,857 2 payments
9. University of Colorado Organisation paid for research $48,816 3 payments
10. Retinovitreous Associates, LTD Organisation paid for research $44,246 2 payments

Usually the institution or organisation running the study, not a person.